Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Direct comparison of distinct naive pluripotent states in human embryonic stem cells.

Warrier S, Van der Jeught M, Duggal G, Tilleman L, Sutherland E, Taelman J, Popovic M, Lierman S, Chuva De Sousa Lopes S, Van Soom A, Peelman L, Van Nieuwerburgh F, De Coninck DIM, Menten B, Mestdagh P, Van de Sompele J, Deforce D, De Sutter P, Heindryckx B.

Nat Commun. 2017 Apr 21;8:15055. doi: 10.1038/ncomms15055.

2.

Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures.

Johnston HE, Carter MJ, Cox KL, Dunscombe M, Manousopoulou A, Townsend PA, Garbis SD, Cragg MS.

Mol Cell Proteomics. 2017 Mar;16(3):386-406. doi: 10.1074/mcp.M116.063511. Epub 2017 Jan 4.

PMID:
28062796
3.

Multiple-Localization and Hub Proteins.

Ota M, Gonja H, Koike R, Fukuchi S.

PLoS One. 2016 Jun 10;11(6):e0156455. doi: 10.1371/journal.pone.0156455. eCollection 2016.

4.

TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia.

Bresin A, D'Abundo L, Narducci MG, Fiorenza MT, Croce CM, Negrini M, Russo G.

Cell Death Dis. 2016 Jan 28;7:e2071. doi: 10.1038/cddis.2015.419. Review.

5.

Non-canonical Activation of Akt in Serum-Stimulated Fibroblasts, Revealed by Comparative Modeling of Pathway Dynamics.

Nim TH, Luo L, White JK, Clément MV, Tucker-Kellogg L.

PLoS Comput Biol. 2015 Nov 10;11(11):e1004505. doi: 10.1371/journal.pcbi.1004505. eCollection 2015 Nov.

6.

The emerging roles of Oct4 in tumor-initiating cells.

Wang YJ, Herlyn M.

Am J Physiol Cell Physiol. 2015 Dec 1;309(11):C709-18. doi: 10.1152/ajpcell.00212.2015. Epub 2015 Oct 7. Review.

7.

miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.

Bresin A, Callegari E, D'Abundo L, Cattani C, Bassi C, Zagatti B, Narducci MG, Caprini E, Pekarsky Y, Croce CM, Sabbioni S, Russo G, Negrini M.

Oncotarget. 2015 Aug 14;6(23):19807-18.

8.

The long journey of TCL1 transgenic mice: lessons learned in the last 15 years.

Pekarsky Y, Drusco A, Kumchala P, Croce CM, Zanesi N.

Gene Expr. 2015;16(3):129-35. doi: 10.3727/105221615X14181438356256. Review.

9.

TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.

Balatti V, Rizzotto L, Miller C, Palamarchuk A, Fadda P, Pandolfo R, Rassenti LZ, Hertlein E, Ruppert AS, Lozanski A, Lozanski G, Kipps TJ, Byrd JC, Croce CM, Pekarsky Y.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2169-74. doi: 10.1073/pnas.1500010112. Epub 2015 Feb 2.

10.

OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells.

Liu TM, Ling Y, Woyach JA, Beckwith K, Yeh YY, Hertlein E, Zhang X, Lehman A, Awan F, Jones JA, Andritsos LA, Maddocks K, MacMurray J, Salunke SB, Chen CS, Phelps MA, Byrd JC, Johnson AJ.

Blood. 2015 Jan 8;125(2):284-95. doi: 10.1182/blood-2014-06-583518. Epub 2014 Oct 7.

11.

Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.

Tang CH, Ranatunga S, Kriss CL, Cubitt CL, Tao J, Pinilla-Ibarz JA, Del Valle JR, Hu CC.

J Clin Invest. 2014 Jun;124(6):2585-98. doi: 10.1172/JCI73448. Epub 2014 May 8.

12.

Role of AKT signaling in DNA repair and clinical response to cancer therapy.

Liu Q, Turner KM, Alfred Yung WK, Chen K, Zhang W.

Neuro Oncol. 2014 Oct;16(10):1313-23. doi: 10.1093/neuonc/nou058. Epub 2014 May 7. Review.

13.

Signaling specificity in the Akt pathway in biology and disease.

Toker A, Marmiroli S.

Adv Biol Regul. 2014 May;55:28-38. doi: 10.1016/j.jbior.2014.04.001. Epub 2014 Apr 19. Review.

15.

ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.

Widhopf GF 2nd, Cui B, Ghia EM, Chen L, Messer K, Shen Z, Briggs SP, Croce CM, Kipps TJ.

Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):793-8. doi: 10.1073/pnas.1308374111. Epub 2013 Dec 30.

16.

Protooncogene TCL1b functions as an Akt kinase co-activator that exhibits oncogenic potency in vivo.

Hashimoto M, Suizu F, Tokuyama W, Noguchi H, Hirata N, Matsuda-Lennikov M, Edamura T, Masuzawa M, Gotoh N, Tanaka S, Noguchi M.

Oncogenesis. 2013 Sep 16;2:e70. doi: 10.1038/oncsis.2013.30.

17.

miR deregulation in CLL.

Balatti V, Pekarky Y, Rizzotto L, Croce CM.

Adv Exp Med Biol. 2013;792:309-25. doi: 10.1007/978-1-4614-8051-8_14. Review.

18.

Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F.

Surg Oncol Clin N Am. 2013 Oct;22(4):641-64. doi: 10.1016/j.soc.2013.06.008. Epub 2013 Aug 6. Review.

19.

Functional analysis of Tcl1 using Tcl1-deficient mouse embryonic stem cells.

Miyazaki T, Miyazaki S, Ashida M, Tanaka T, Tashiro F, Miyazaki J.

PLoS One. 2013 Aug 5;8(8):e71645. doi: 10.1371/journal.pone.0071645. Print 2013. Erratum in: PLoS One. 2013;8(11). doi:0.1371/annotation/cc1568d0-4299-47b9-896b-d1d12b551224.

20.

A role for IRF4 in the development of CLL.

Shukla V, Ma S, Hardy RR, Joshi SS, Lu R.

Blood. 2013 Oct 17;122(16):2848-55. doi: 10.1182/blood-2013-03-492769. Epub 2013 Aug 7.

Supplemental Content

Support Center